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Interaction of the human immunodeficiency virus type 1 (HIV-1) gp120 envelope glycoprotein with the
primary receptor, CD4, promotes binding to a chemokine receptor, either CCR5 or CXCR4. The chemokine
receptor-binding site on gp120 elicits CD4-induced (CD4i) antibodies in some HIV-1-infected individuals. Like
CCR5 itself, the CD4i antibody 412d exhibits a preference for CCR5-using HIV-1 strains and utilizes sulfated
tyrosines to achieve binding to gp120. Here, we show that 412d binding requires the gp120 ␤19 strand and the
base of the V3 loop, elements that are important for the binding of the CCR5 N terminus. Two gp120 residues
in the V3 loop base determined 412d preference for CCR5-using HIV-1 strains. A chimeric molecule in which
the 412d heavy-chain third complementarity-determining loop sequence replaces the CCR5 N terminus functioned as an efficient second receptor, selectively supporting the entry of CCR5-using HIV-1 strains. Sulfation
of N-terminal tyrosines contributed to the function of this chimeric receptor. These results emphasize the close
mimicry of the CCR5 N terminus by the gp120-interactive region of a naturally elicited CD4i antibody.
entry (15, 16). The CCR5 N terminus is electronegative; in
addition to being rich in acidic residues, several of the tyrosines
in this segment are sulfated posttranslationally (18). The negatively charged tyrosine sulfates contribute to the efficiency of
gp120 binding and HIV-1 entry (8). Sulfated peptides corresponding in sequence to the CCR5 N terminus bind gp120
glycoproteins from CCR5-using (R5) HIV-1 strains after incubation with soluble CD4 (sCD4) (11, 17, 19). Studies of gp120
mutants suggest that the binding of the CCR5 N terminus
requires sequences in the ␤19 strand and the base of the V3
loop (12, 17). Other gp120 sequences near the tip of the V3
loop are thought to contribute to the ability of gp120 to interact with the body of the chemokine receptor (22, 34, 35). Both
sets of interaction are required for functional, high-affinity
gp120-CCR5 binding leading to virus entry.
The binding sites for CD4 and chemokine receptor on the
HIV-1 gp120 envelope glycoprotein serve as targets for neutralizing antibodies generated during natural infection. Some
potent neutralizing antibodies, such as immunoglobulin G1b12,
bind near the CD4-binding site of gp120 (38, 48). Other monoclonal antibodies derived from HIV-1-infected individuals recognize a conserved gp120 structure that is closely related to the
chemokine receptor-binding site. The binding of these antibodies to gp120 is induced by CD4 binding; hence, they are
designated CD4-induced (CD4i) antibodies (41). CD4i antibodies block the binding of gp120-sCD4 complexes to the
chemokine receptors (42, 43). CD4i antibodies exhibit various
degrees of potency in neutralizing HIV-1. The neutralizing
efficacy of CD4i antibodies is limited by steric constraints on
antibody binding after the HIV-1 envelope glycoproteins have
engaged the CD4 glycoprotein on the target cell surface (27).
Some CD4i antibodies have long complementarity-determin-

Human immunodeficiency virus type 1 (HIV-1) entry into
target cells is mediated by sequential binding to the primary receptor, CD4, and either of two coreceptors, CCR5
or CXCR4 (1, 3, 7, 13, 14, 20, 29). CD4 binding to the HIV-1
gp120 exterior envelope glycoprotein results in a change in
gp120 conformation that is favorable for CCR5 or CXCR4 binding (42, 43). Receptor binding is thought to trigger further
conformational changes in the HIV-1 envelope glycoproteins,
ultimately leading to fusion of the viral and cell membranes.
The binding sites for CD4 and the CCR5 or CXCR4 chemokine receptors on the HIV-1 gp120 glycoprotein are potential targets for intervention. The HIV-1 gp120 glycoprotein is
composed of regions conserved among virus strains (C1 to C5)
and regions that exhibit significant variation (V1 to V5). The
binding site for CD4 has been visualized by x-ray crystallography and includes a highly conserved pocket on the gp120 surface (25, 26). The gp120 structures involved in chemokine
receptor binding include the well-conserved ␤19 strand and the
third variable (V3) loop, which governs chemokine receptor
choice (2, 23, 30, 35, 39). Most of the HIV-1 strains that are
transmitted horizontally and that predominate in the first few
years of infection utilize CCR5 as a coreceptor (28, 31, 33).
Thus, understanding gp120-CCR5 interaction may facilitate
the development of effective therapies and vaccines.
Like all G protein-coupled receptors, CCR5 and CXCR4
are thought to span the membrane seven times. The CCR5 N
terminus and second extracellular loop have been shown to be
important for the ability of the receptor to support HIV-1
* Corresponding author. Mailing address: Jimmy Fund Building,
Room 824, Dana-Farber Cancer Institute, 44 Binney St., Boston, MA
02115. Phone: (617) 632-3371. Fax: (617) 632-4338. E-mail: joseph
_sodroski@dfci.harvard.edu.
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ing region 3 (CDR3) loops on their heavy chains (8, 21). These
long CDR3 loops may allow CD4i antibodies to access conserved gp120 structures in the ␤19 strand and V3 base, bypassing the variable gp120 loops that protect these conserved elements. In some cases, sulfated tyrosine residues on the heavychain CDR3 loops contribute to the interaction of the CD4i
antibody with HIV-1 gp120 (8). Thus, several of the CD4i
antibodies appear to mimic the CCR5 receptor.
One CD4i antibody, 412d, preferentially recognizes gp120
glycoproteins from CCR5-using HIV-1 strains (8). When a
number of gp120 glycoproteins from different HIV-1 variants
were examined, a strong correlation was observed between
412d binding and the ability of the gp120 glycoprotein to use
CCR5 as a second receptor. Thus, the 412d antibody appears
to mimic CCR5 quite closely. Here, we characterize the gp120
epitope for the 412d antibody. To examine whether the structural similarity of the 412d antibody and CCR5 translates into
functional similarity, we replaced the CCR5 N terminus by
sequences of the 412d heavy-chain CDR3 loop. The ability of
these chimeric receptors to support the entry of a variety of
HIV-1 strains was tested.
MATERIALS AND METHODS
Cell lines and antibodies. The 293T cells were used for expressing HIV-1
gp120 proteins and also for producing recombinant viruses. Cf2Th cells were
used for expressing CD4 and CCR5 or CXCR4 to study the entry of viruses and
antibody neutralization.
The human monoclonal antibody 412d was isolated from an Epstein-Barr
virus-transformed B-cell line, which was established from an HIV-1-infected
individual (AC-01) undergoing early structured treatment interruption (37). Epstein-Barr virus transformation of B cells was performed as previously described
(36). The antibody was purified on protein A-Sepharose and eluted with 3 M
MgCl2 at room temperature.
Construction of HIV-1 envelope glycoprotein and CCR5 mutants. The panel of
HIV-1 YU2 gp120 mutants used for 412d epitope mapping was made by sitedirected mutagenesis as previously described (35). The starting plasmid, YU2wt⌬,
encodes a gp120 derivative from the YU2 HIV-1 strain containing deletions of
gp120 residues 31 to 81 and 128 to 194, which represent the N terminus and
V1/V2 variable loops, respectively.
The overlap-PCR approach was employed to generate mutations and deletions for the V3 loop-deletion mutants of the envelope glycoproteins of the
HXBc2 and ADA HIV-1 strains. The latter envelope glycoproteins were expressed by as ADA ⌬V1/2gp160 glycoproteins. The V3 loop exchange mutants in
the HXBc2, ADA, YU2, and MN envelope glycoproteins; the human CCR5 N
terminus deletion mutants; and the chimeric CCR5 mutant containing the 412d
CDRH3 loop were all made by the overlap-PCR approach. All introduced
changes were confirmed by DNA sequencing.
Numbering of the gp120 amino acid residues is based on the sequence of the
prototypic HXBc2 strain of HIV-1, according to current conventions (24).
Expression and analysis of CCR5 variants. The wild-type CCR5 and CCR5
variants were expressed from plasmids containing a codon-optimized CCR5 gene
and have a C-terminal C9 epitope tag. For analysis of sulfation, Cf2Th cells in a
100-mm dish were transfected using Effectene (QIAGEN). The cells were
washed three times in PBS and then used for cysteine/methionine labeling or
sulfate labeling. For cysteine/methionine labeling, cells were incubated overnight
in cysteine/methionine-free Dulbecco’s modified Eagle medium (DMEM) with
200 Ci (each) of 35S-labeled cysteine and 35S-labeled methionine (Protein
Labeling Mix; Perkin-Elmer). For sulfate labeling, cells were incubated in sulfate-free medium (M8028; Sigma) with 500 Ci of 35S-sulfate (Na235SO4; Perkin-Elmer) for 1 day at 37°C. Cells were lysed in solubilization buffer, consisting
of 1% CHAPSO {3-[(-cholamidopropyl) dimethylammonio]-2-hydroxyl-1-propanesulfonic acid}, 10% glycerol, 20 mM Tris, pH 7.5, 100 mM (NH4)2SO4, and
protease inhibitors, and incubated at 4°C for 45 min with rocking. The cell lysates
were cleared by centrifugation at 14,000 ⫻ g for 15 min at 4°C. The cleared
lysates were incubated with the anti-C9 antibody 1D4 and protein A-Sepharose
beads. The precipitated CCR5 proteins were visualized by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and autoradiography.
To produce target cells for HIV-1 infection, Cf2Th-CD4 cells were transfected
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FIG. 1. Inhibition of gp120 binding to CCR5 by the 412d antibody.
Radiolabeled YU2 HIV-1 gp120 glycoprotein was incubated in the
presence of sCD4 (10 g/ml) with Cf2Th-CCR5 cells. The incubation
was performed in the absence (no Ab) or presence of the 17b, 412d, or
C11 antibody. The bound gp120 glycoprotein was detected by lysis of
the Cf2Th-CCR5 cells and precipitation with sera pooled from HIV1-infected individuals.

with plasmids expressing wild-type or variant CCR5 proteins. An aliquot of the
transfected cells was stained with phycoerythrin-conjugated anti-human CCR5
antibody, 2D7, and analyzed by fluorescence-activated cell sorter. The remaining
cells were used for infection by recombinant HIV-1 expressing luciferase, as
described below.
Transient expression of HIV-1 envelope glycoproteins. 293T cells grown to
70% confluence in 100-mm dishes were transfected with 4 g of an envelope
protein-expressing plasmid DNA and 1 g of an HIV-1 Tat-expressing plasmid
DNA with the Effectene transfection reagent (QIAGEN). One day later, the
medium was removed, the cells were washed once with 10 ml of phosphatebuffered saline (PBS), and labeling medium (4.5 ml of DMEM; 0.5 ml of heatinactivated, dialyzed FBS; 50 g of penicillin-streptomycin solution) and 20 l
(⬃230 Ci) of 35S-methionine protein labeling mixture were added. The cells
were incubated at 37°C for another day. The medium was harvested, centrifuged
to remove cells debris, and then stored at 4°C.
Immunoprecipitation of envelope glycoproteins. For precipitation of radiolabeled HIV-1 envelope glycoproteins, 100 l of medium (for soluble gp120 expression) or 400 l of medium (for full-length gp160) containing the labeled
proteins was incubated overnight with 100 l of 10% protein A-Sepharose
(Pharmacia), 50 l of 4% bovine serum albumin, and 1 g of monoclonal
antibody with or without sCD4 (8 to 10 g/ml) or, instead of the monoclonal
antibody, 2 l of a mixture of sera from HIV-1-infected individuals. PBS was
added to bring the total volume to 1 ml. The Sepharose beads were then washed
twice with 1 ml of 0.5 M NaCl in PBS and once with 1 ml of PBS. The beads were
mixed with 2⫻ gel loading buffer and boiled for 3 min. Following the removal of
the beads by centrifugation, the supernatants were loaded on a 10% SDS-PAGE
gel. The gel was enhanced with Autoflour (National Diagnostic) for 45 min
before being dried at 80°C for 2 h and exposed to film. The gel was also used for
PhosphorImager (Molecular Dynamics) analysis.
Virus preparation. Recombinant HIV-1 containing the firefly luciferase gene
was produced by transfection of 293T cells with the pCMV-Gag-Pol packaging
plasmid, the pHIV-luc vector, and the pSVIIIenv plasmid expressing the wildtype or mutant envelope glycoproteins. Three days after transfection, the cell
supernatants were harvested, assayed for virus by reverse transcriptase measurement, and frozen in aliquots.
Virus infection assay. The Cf2Th cells expressing CD4 and either wild-type or
mutant CCR5 were seeded at a density of 6,000 cells/well in a 96-well plate and
cultured overnight at 37°C. About 2,000 reverse transcriptase units of virus were
incubated with the cells overnight at 37°C in a 50-l volume. Then, 200 l of
fresh medium was added to the cells, and the cells were cultured for 2 days. The
cells were washed once with PBS and lysed with 30 l of luciferase lysis buffer.
The plates were stored in a ⫺80°C freezer until the assays were performed.
Luciferase assays were performed with the EG & G Berthold Microplate Luminometer LB 96V (Promega).
Neutralization assay. The viral entry and neutralization assays were performed in 24-well plates for the wild-type HXBc2 and the HXBc2 NM/DI
asparagine/methionine (NM) mutant, in which the asparagine/methionine (NM)
pair was changed to aspartic acid/isoleucine (DI). Cf2Th-CD4/CCR5 cells were
used to examine the use of CCR5 for entry by the HXBc2 NM/DI mutant.
Cf2Th-CD4/CXCR4 cells were used to test the sensitivity of the viruses to
neutralization by the 412d antibody. Viruses were incubated with 10 g/ml 412d
in 0.5 ml of DMEM for 60 min at 37°C. The virus-antibody mixtures were then
transferred to wells containing the target Cf2Th-CD4/CCR5 cells. After overnight incubation, 1.5 ml of fresh medium was added to each well, and the cells
were cultured for 2 more days. The cells were then lysed and assayed for
luciferase activity (Tuner 20; Promega).
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FIG. 2. Precipitation of HIV-1 gp120 mutants by the 412 antibody. Radiolabeled wt⌬ or mutant derivatives were incubated with the 412d
antibody in the absence (⫺) or presence (⫹) of sCD4 (8 g/ml). The precipitated proteins are shown. The indicated conserved region (C1-C4)
or the V3 region represents the location of the altered amino acid residue on the primary HIV-1 gp120 sequence.

RESULTS
Mapping of the 412d epitope. The CD4i monoclonal antibody 412d is derived from an HIV-1-infected individual,
AC-01 (8, 37). As has been found for other CD4i antibodies

(42–46), the 412d antibody blocked the ability of HIV-1 gp120sCD4 complexes to bind the CCR5 receptor (Fig. 1).
To characterize the gp120 epitope of 412d, a panel of 30
YU2 gp120 mutants was tested for 412d recognition, as previ-

FIG. 3. Effect of gp120 V3 loop deletions on 412d recognition. (a)
The sequences of the gp120 V3 loop of the X4 HIV-1 strain HXBc2,
the R5X4 strain 89.6, and the R5 strains YU2 and ADA are aligned.
The conserved sequences are boxed. The asterisks indicate the particular amino acid residues altered in this study. The extent of the deletions made in the HXBc2 and ADA gp120 glycoproteins is indicated by
the horizontal arrows; the linkers substituted for the deleted residues
are indicated in parentheses next to the name of the mutant. The
⌬V3-12 and ⌬V3-20 constructs were made for the HXBc2 gp120 glycoprotein only. The V3 deletion mutants in the ADA envelope glycoproteins were constructed in the context of the ⌬V1/2 gp120 glycoprotein. The numbering scheme is based on that recommended by Korber
et al. (24). (b) Precipitation of the ADA ⌬V1/2 envelope glycoprotein
and mutant derivatives by the 412d antibody in the absence and presence of 10 g/ml sCD4 is shown. Precipitation of the proteins by
pooled sera (P.S.) from HIV-1-infected individuals is also shown. The
two bands represent glycoforms of the ⌬V1/2 gp120 glycoprotein (data
not shown).
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FIG. 4. Effect of V3 loop exchange on gp120 recognition by the
F425b and 412d antibodies. The gp120 glycoproteins of the X4 HXBc2
and MN HIV-1 strains, the R5X4 89.6 HIV-1 strain, and the R5 YU2
and ADA HIV-1 strains were precipitated by the indicated monoclonal
antibody or by pooled sera (P.S.) from HIV-1-infected individuals. In
addition, chimeric gp120 glycoproteins in which the gp120 V3 loop or
V3 loop and residue 440 derived from a heterologous strain were tested.
For example, the HXBc2(YU2V3) glycoprotein contains the V3
loop from the YU2 gp120 in the background of the HXBc2 gp120
glycoprotein.

ously described (44, 46). The amount of each mutant gp120
protein in the reaction was normalized by precipitating the
samples in parallel with a mixture of polyclonal sera from
HIV-1-infected individuals (data not shown). In the absence of
sCD4, compared with recognition of wild-type gp120, recognition by the 412d antibody was significantly reduced for several gp120 mutants tested (e.g., 117K/D, 121K/D [C1 region],
207K/D, 257T/D [C2 region], 383F/S [C3 region], and 435Y/S
[C4 region]). However, 412d binding to these mutants could be
largely restored by adding sCD4. By contrast, even in the presence of sCD4, 412d did not efficiently precipitate the 420I/R
mutant, which alters the ␤19 strand of gp120, or the 298R/G
mutant, which alters the V3 loop (Fig. 2). Deletion of the entire V3 loop also abolished 412d binding, even in the presence
of sCD4 (Fig. 2). The 381E/R mutant is disrupted for binding
several conformation-dependent ligands (35, 44, 46), explaining its inefficient precipitation by the 412d antibody. In comparison with previously described epitope maps for CD4i antibodies such E51, 17b, and 23e, the gp120 residues important
for 412d binding are located in an overlapping region of gp120.
However, unlike most CD4i antibodies (44–46), the 412d antibody requires elements of the gp120 V3 loop for recognition.
Thus, the 412d antibody epitope includes the ␤19 strand and
V3 loop of HIV-1 gp120.
V3 loop sequences critical for 412d recognition. The 412d
antibody is unusual among CD4i antibodies in demonstrating a
marked preference for the gp120 glycoproteins of CCR5-using
HIV-1 isolates (8). As CCR5 use is dictated by sequences in
the V3 loop (5, 22) and 412d recognition demonstrates a strong
and unusual dependence on the integrity of the V3 loop, we
wished to define better the V3 elements that contribute to 412d
binding. The effect of changes in arginine 298 on 412d binding
suggested the importance of the base of the V3 loop to 412d
recognition. Therefore, a set of deletions extending from the
V3 tip was created and analyzed (Fig. 3a). Figure 3b shows that
the ⌬V3-16 and ⌬V3-18 glycoproteins were precipitated by the
412d antibody in both the absence and presence of sCD4. By
contrast, the ⌬V3 and ⌬V3-15 glycoproteins were not efficient-
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ly recognized by the 412d antibody. We conclude that the 17
residues at the base of the V3 loop are important for 412d
recognition of gp120.
The 412d antibody specifically precipitates the gp120 glycoproteins of the CCR5-using HIV-1 strains, YU2 and ADA, and
the dualtropic (R5X4) strain 89.6, but not the gp120 from the
CXCR4-using HXBc2 or MN strains (Fig. 4). A V3 loopdirected antibody, F425b, recognized the MN, ADA, YU2, and
89.6 gp120 glycoproteins but did not precipitate the HXBc2
gp120 glycoprotein (Fig. 4). To examine the gp120 determinants
of this differential recognition, we utilized chimeric gp120 glycoproteins that contained the V3 loop from a heterologous
strain. Some chimerae contained a heterologous V3 loop and
an amino acid (residue 440) from the fourth conserved region
of gp120. These changes in gp120 have been shown to alter
chemokine receptor preference (4, 8). The HXBc2(YU2V3) glycoprotein, which contains the V3 loop of the YU2 R5 HIV-1
strain in the background of HXBc2 gp120, was efficiently recognized by the 412d and F425b antibodies. This result indicates
that the V3 loop is the major determinant of the poor recognition of the HXBc2 gp120 glycoprotein by these antibodies.
The V3 loop was also the determinant of the differential recognition of the MN and ADA gp120 glycoproteins by the 412d
antibody (Fig. 4). Chimeric gp120 glycoproteins derived from
the MN strain but containing the ADA V3 loop [MN(ADAV3)
and MN(ADAV3 plus E440R)] were efficiently precipitated by
the 412d antibody. By contrast, chimeric gp120 glycoproteins
derived from the ADA strain but containing MN V3 loop
[ADA(MNV3) and ADA(MNV3 plus R440E)] were not precipitated by the 412d antibody. The alteration of residue 440,
which can influence the efficiency of CXCR4 usage (4, 19, 47),
had no significant effect on 412d recognition. The MN-ADA
chimeric gp120 glycoproteins were all precipitated by the
F425b antibody, as expected from the efficient recognition of
the MN and ADA parent glycoproteins. These results demonstrate that variation in V3 loop sequences accounts for the
different recognition of gp120 from distinct HIV-1 strains by
the 412d and F425b CD4i antibodies.
We wished to further define the differences between the
HXBc2 and YU2 V3 loop that accounted for the differences in

FIG. 5. Precipitation of HXBc2 V3 loop deletion mutants by the
412d antibody. The indicated HXBc2 wild-type (WT) or mutant gp120
envelope glycoproteins were precipitated either by the 412d antibody
in the presence of 10 g/ml sCD4 or by pooled sera (P.S.) from
HIV-1-infected individuals.
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412d recognition. Because the base of the V3 loop is similar in
these two gp120 glycoproteins, we hypothesized that sequences
in the tip of the HXBc2 V3 loop might play an inhibitory role
in 412d binding. To test this, progressive deletions of the tip of
the V3 loop were made in the HXBc2 gp120 envelope glycoprotein. The ⌬V3-20 and ⌬V3-18 glycoproteins, which are
missing the V3 tip (Fig. 3a), were recognized by the 412d
antibody slightly better than the wild-type HXBc2 gp120 glycoprotein (Fig. 5). Additional deletion of V3 residues resulted
in loss of 412d recognition (⌬V3-16 and ⌬V3-12) (Fig. 5).
Thus, sequences in the HXBc2 V3 tip may contribute to the
poor recognition of the HXBc2 gp120 glycoprotein by the 412d
antibody. However, even the ⌬V3-18 mutant is recognized
inefficiently by 412d compared with the HXBc2 (YU2V3) glycoprotein (Fig. 5). Therefore, other sequence differences between the HXBc2 and YU2 V3 loops apparently account for
the differential recognition by the 412d antibody.
Comparison of the sequences in the base of the V3 loop of
the HXBc2 and YU2 gp120 glycoproteins reveals differences in
amino acid residues 325 and 326 (Fig. 3a). These residues are
asparagine and methionine in the HXBc2 gp120 but are aspartic acid and isoleucine in the gp120 glycoproteins of viruses
that can utilize CCR5 as a coreceptor. Alteration of the asparagine-methionine pair in the HXBc2 ⌬V3-16 glycoprotein to
aspartic acid-isoleucine resulted in efficient recognition by the
412d antibody (Fig. 6a). These changes were not sufficient to
allow this envelope glycoprotein to bind two other antibodies,
the CD4i F425b (6) antibody or the V3 loop-directed 39F
antibody (Fig. 6a). The altered HXBc2 ⌬V3-16 glycoprotein
was not able to bind CCR5-expressing cells (Fig. 6a), consistent with the documented role of the V3 tip in chemokine
receptor binding (2, 10, 35).
We also examined the effect of changes in residues 325 and
326 in the context of the complete HXBc2 gp120 glycoprotein
(Fig. 6b). The aspartic acid-isoleucine substitutions at these
positions in the HXBc2 gp120 allowed 412d recognition but
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FIG. 6. Effect of changes in residues 325 and 326 on 412d recognition. (a) The HXBc2 ⌬V3-16 glycoproteins containing either asparagine/methionine (NM) or aspartic acid/isoleucine (DI) at V3 loop
positions 325 and 326 were precipitated by the indicated monoclonal
antibodies or by pooled sera (P.S.) from HIV-1-infected humans. All
envelope glycoproteins were incubated with 10 g/ml sCD4 prior to
immunoprecipitation. The F425b and 39F antibodies are directed
against the V3 loop. The ability of the envelope glycoproteins to bind
CCR5-expressing cells is shown in the right panel (CCR5). (b) The
precipitation of the indicated full-length gp120 glycoproteins by the
412d antibody in the presence of 10 g/ml sCD4 is shown in the top
panel. The ability of the envelope glycoproteins to bind Cf2Th-CCR5
cells after incubation with 10 g/ml sCD4 is shown in the bottom
panel. (c) Luciferase activity in Cf2Th-CD4/CCR5 cells incubated with
recombinant luciferase-expressing HIV-1 viruses containing the indicated HIV-1 envelope glycoproteins is shown. (d) Recombinant luciferase-expressing viruses with the wild-type HXBc2 or HXBc2 NM/DI
envelope glycoproteins were used to infect Cf2Th-CD4/CXCR4 cells.
In some cases, viruses were first incubated with the 412d antibody.
Luciferase activity in the target cells is shown. Data in panels c and d
represent the means and standard deviation derived from two independent experiments.

not CCR5 binding (HXBc2 NM/DI) (Fig. 6b). We conclude
that the major determinants of the differential recognition by
the 412d antibody of gp120 glycoproteins of the HXBc2 HIV-1
strain and CCR5-using strains are the residues at positions 325
and 326. CCR5 binding apparently has other requirements besides the changes in these residues. Consistent with this interpretation, when recombinant HIV-1 luciferase vectors were
pseudotyped with the different envelope glycoproteins, neither
the HXBc2 nor the HXBc2 NM/DI envelope glycoproteins was
able to support entry into cells expressing CD4 and CCR5 (Fig.
6c). Both of these envelope glycoproteins mediated efficient
entry into cells expressing CD4 and CXCR4 (Fig. 6d). Moreover, infection mediated by the HXBc2 NM/DI envelope glycoproteins, but not that mediated by the HXBc2 NM/DI envelope glycoproteins, was neutralized by the 412d antibody.
These results demonstrate that the requirements for 412d antibody binding and CCR5 recognition can be separated in the
context of a functional HIV-1 envelope glycoprotein.
Functional mimicry of the CCR5 N terminus by the 412
antibody. Several lines of evidence indicate that the heavychain CDR3 loops of the CD4i antibodies play a major role in
contacting gp120 (21, 25, 26). The similarities, including the
presence of sulfated tyrosines, between the heavy-chain CDR3
of some CD4i antibodies (such as 412d) and the CCR5 N
terminus prompted us to ask whether these structures might be
functionally equivalent. The N terminus of CCR5 was replaced
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FIG. 6—Continued.

by sequences derived from the heavy-chain CDR3 loop of the
412d antibody (N412dR5) (Fig. 7a). To examine the contribution of tyrosine sulfation to the functional activity exhibited by
this chimeric protein, the N412dR5-FF mutant was created
(Fig. 7a). In this mutant, two of the tyrosine residues in the
412d heavy-chain CDR3 insert were converted to phenylalanine, preventing the addition of sulfate at these sites. We also
examined the function of a CCR5 protein lacking the N terminus (⌬NR5) (Fig. 7a). The ⌬NR5 protein was previously
shown to be efficiently expressed on the cell surface but is
significantly decreased in its ability to support the entry of
R5 HIV-1 (17). Plasmids expressing the wild-type and mutant CCR5 proteins were transfected into Cf2Th canine thymocytes, which were radiolabeled with 35S-cysteine/methionine or 35S-sulfate. All of the CCR5 variants were expressed
and, with the exception of the ⌬NR5 mutant, incorporated

labeled sulfate (Fig. 7b). The N412dR5-FF mutant was labeled
with 35S-sulfate, suggesting that the two tyrosines remaining in
the N terminus of this protein may be modified by sulfation.
The plasmids expressing the wild-type and mutant CCR5
proteins were transfected into Cf2Th cells expressing CD4, and
the cell surface expression of the CCR5 variants and the susceptibility of these cells to recombinant luciferase-expressing
viruses with various HIV-1 envelope glycoproteins were examined. All four CCR5 variants were expressed equivalently on
the cell surface (Fig. 7c). The N412dR5 protein functioned as
a receptor for viruses with the YU2, ADA, and JR-FL HIV-1
envelope glycoproteins as efficiently as wild-type CCR5 (Fig.
7d and data not shown). The N412dR5 protein was less efficient than wild-type CCR5 in supporting infection by dualtropic viruses from clade B (89.6), clade C (SA32, MCGP1.3,
and 9279), and clade E (CF402) (Fig. 7d and data not shown).
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FIG. 7. Functional replacement of the CCR5 N terminus with the
412d heavy-chain CDR3 sequence. (a) The sequences of the CCR5 N
terminus, the 412d heavy-chain CDR3, and the chimeric receptor
constructs are shown. The ⌬NR5 mutant has a deletion affecting the N
terminus of CCR5. (b) Cf2Th cells expressing the indicated CCR5
variants were radiolabeled with 35S-cysteine/methionine (CYS/MET)
or 35S-sulfate (SO4). The lysates were precipitated with the 1D4 antibody directed against the C9 C-terminal epitope tag on the CCR5
variants. Precipitates were analyzed by SDS-PAGE and autoradiography. (c) Cf2Th-CD4 cells expressing the indicated CCR5 variants were
incubated with phycoerythrin-conjugated 2D7 antibody and analyzed
by fluorescence-activated cell sorter. (d) The graph shows the luciferase activity in target Cf2Th-CD4 cells expressing the indicated CCR5
variants, following incubation with recombinant luciferase-expressing
HIV-1 containing the indicated HIV-1 envelope glycoproteins. The
values shown represent the means and standard deviation of four
replicate experiments. Because of the high level of infectivity of the
virus with the HXBc2(YUV3) glycoproteins, the values shown represent 1/10 of the actual luciferase activity observed.

The integrity of the tyrosine residues in the substituted 412d
CDR3 sequence contributes to the efficiency of the receptor
activity (see N412dR5-FF in Fig. 7d). Neither wild-type CCR5
nor the N412dR5 protein supported infection of X4 viruses
(HXBc2 and MN) (Fig. 7d). Utilization of wild-type CCR5 and
N412dR5 was determined by V3 loop sequences [compare
HXBc2 and HXBc2(YUV3) or MN and MN(ADAV3) in Fig.
7d]. We conclude that the 412d heavy-chain CDR3 loop sequence can functionally replace the CCR5 N terminus with
respect to its activity and specificity as an HIV-1 receptor.
DISCUSSION
Binding of the HIV-1 gp120 glycoprotein to the CCR5 chemokine receptor is thought to involve two sets of contacts: (i)
the interaction of the ␤19 strand and V3 loop of gp120 with the
CCR5 N terminus and (ii) the binding of the tip of the V3 loop
to the body of the chemokine receptor. These CCR5-interactive elements of gp120 are more conserved than the sequences
along the flanks of the V3 loop, variations which can determine
chemokine receptor preference (4, 22, 32, 40). Additional variation in V3 sequences is probably driven by pressure from
neutralizing antibodies directed against both variable and
more conserved gp120 structures. The CD4i antibodies presumably contribute to the selection of virus variants with minimal spontaneous exposure of the chemokine receptor-binding
site on the envelope glycoprotein complex.
All CD4i antibodies bind gp120 better after CD4 binding
and block the binding of gp120-sCD4 complexes to the chemokine receptor (41–43, 46). They do so by interacting with
the first of the two chemokine receptor-binding surfaces on

gp120 described above, i.e., the contacts for the N terminus of
the chemokine receptor. The gp120 ␤19 strand and V3 loop
base represent the most positively charged structures on the
gp120 surface (25, 26) and thus complement the acidic N
termini of the chemokine receptors. Contributing to this acidity are sulfated tyrosines in the N termini of both CCR5 and
CXCR4. These sulfotyrosine residues are particularly important for HIV-1 entry via CCR5 (8, 11, 12, 15, 18). Some CD4i
antibodies, like 412d, have evolved sulfated tyrosines in their
long heavy-chain CDR3 loops that capitalize on the increased
opportunities for molecular contacts with gp120 afforded by
this posttranslational modification (8, 21). The 412d antibody
is unusual among CD4i antibodies in exhibiting a marked preference for the gp120 glycoproteins of CCR5-using HIV-1
strains (8). Our results indicate that the amino acid residues at
positions 325 and 326 in the base of the V3 loop are the major
determinants of this 412d preference. Examination of the V3
loop sequences of numerous HIV-1 strains reveals that the
aspartic acid-isoleucine pair, which is preferred by the 412d
antibody, is much more common than the asparagine-methionine pair found in the HXBc2 gp120. As the 412d antibody
was derived from an HIV-1-infected individual (8, 37), the
viruses that elicited this antibody most likely had V3 sequences
resembling the aspartic acid-isoleucine pair. Changes in residues 325 and 326 have been shown to decrease CCR5 binding
(10), so the aspartic acid-isoleucine pair may also contribute to
the interaction with the CCR5 N terminus. Our results, however, clearly indicate that CCR5 binding and utilization require
specific V3 loop structures other than those specified by residues 325 and 326. Thus, the V3 loop requirements for CCR5
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binding are more stringent than those for 412d recognition.
For CCR5 N-terminal peptides and for 412d, deletions affecting only the tip of the V3 loop have little effect on binding; on
the other hand, the V3 tip is required for binding the complete
CCR5 protein (10, 12, 35). This is consistent with a model in
which the 412d heavy-chain CDR3 loop mimics only the CCR5
N terminus and not the remainder of the CCR5 molecule,
which contributes necessary contacts with the V3 loop tip.
The 412d heavy-chain CDR3 sequences effectively substitute
for the natural CCR5 N terminus in supporting HIV-1 infection. This suggests that the two sets of gp120-CCR5 contacts
described above are not significantly misaligned by this substitution. Dualtropic HIV-1 strains utilized the chimeric receptor
somewhat less efficiently than wild-type CCR5, possibly related
to their generally lower affinity for CCR5 than that exhibited
by pure R5 viruses (9). The chimeric receptor exhibited the
same preference for different HIV-1 strains as CCR5 itself.
These results underscore the high degree to which the 412d
antibody mimics the CCR5 N terminus. Although not fully
understood, the structural requirements in the CCR5 N terminus for gp120 binding extend beyond the mere presence of
sulfotyrosine and acidic residues. For example, the tyrosinesulfated CXCR4 N terminus inefficiently substitutes for the
CCR5 N terminus in supporting infection by R5 HIV-1 isolates
(32). Studies in which individual CCR5 N-terminal residues
were altered indicate that some specificity for the tyrosines at
particular locations exists (15, 16).
Further attempts to define the precise interaction of the
412d antibody with gp120 are warranted. Our results suggest
that such information may provide important insights into the
interaction of gp120 and CCR5.
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